Introduction {#S1}
============

Pathogenic *Candida* species can cause invasive candidiasis that takes more than 50,000 lives worldwide annually, and it also causes recurrent vulvovaginal candidiasis that affects approximately 138 million women annually ([@B16]; [@B8]). *Candida albicans* candidiasis infections are the most well-known, but non-*albicans* candidiasis infections have also increased in recent years ([@B18]). *Candida krusei* candidiasis infections are of particular concern because *C. krusei* is inherently resistant to fluconazole, a common drug used for antifungal treatment, and *C. krusei* fungemia can cause high mortality rates ranging from 60 to 80% ([@B1]; [@B19]; [@B28]). Finding an effective way of controlling vulvovaginal candidiasis caused by fluconazole-resistant *Candida* species is an important problem because there are only a few effective therapeutic drugs that can be used on vulvovaginal candidiasis patients ([@B29]; [@B30]).

Although echinocandins such as caspofungin are currently the drugs of choice for treatment of invasive *C. krusei* candidiasis infections, echinocandin-resistant isolates caused by point mutations in the *FKS1* gene have increased ([@B14]; [@B10]; [@B17]). Some studies have shown that *C. krusei* has considerable resistance to the antifungal drugs itraconazole and amphotericin B, and others have shown that it has become a multidrug-resistant pathogen ([@B23]; [@B12]; [@B25]). It has become essential to develop antifungal agents with novel antifungal mechanisms for the treatment of candidiasis caused by *C. krusei*.

Miltefosine, an alkylphosphocholine, was initially developed as an antitumor drug, but it is now a clinically licensed antiparasitic drug ([@B9]). Miltefosine is an oral anti-*Leishmania* drug, and the pharmacokinetics of miltefosine in children and adults showed high miltefosine plasma concentrations (i.e., 17--42 μg/mL) for the treatment of cutaneous leishmaniasis ([@B4]). Miltefosine is a less toxic drug; some clinical trials have shown that no treatment-related serious adverse events were reported for the treatment of leishmaniasis both in children and adults, although adverse events were usually reported ([@B39]; [@B35]; [@B20]).

Miltefosine has also been found to possess antifungal potential; both *in vitro* and *in vivo* activities against *Cryptococcus* yeasts have been observed ([@B40]). The *in vitro* antifungal activities of miltefosine against dermatophytes, *Paracoccidioides* yeasts, and *Candida auris* were found one after another ([@B33]; [@B27]; [@B41]). It has been reported that miltefosine has the *in vivo* efficacy in a murine model of oral candidiasis caused by *C. albicans* ([@B37]). In previous studies, miltefosine displayed good therapeutic effects against vaginal candidiasis in mice and against candidiasis and cryptococcosis in the larval models of *Galleria mellonella* ([@B7]; [@B31]). Many studies have established the activity of miltefosine against *Candida* species planktonic cells and biofilms ([@B38], [@B36]), but the antifungal effect of miltefosine against *C. krusei* has not been reported.

Data on susceptibility profiles of *C. krusei* isolates from patients with vulvovaginal candidiasis are limited. In this work, we first assessed the antifungal susceptibility patterns of *C. krusei* isolates from vulvovaginal candidiasis patients. We examined the antifungal activity of miltefosine against 57 clinical isolates of *C. krusei*. We assessed the efficacy of miltefosine in combination with azoles and amphotericin B against *C. krusei* planktonic cells and biofilms. We also evaluated the potential mechanism of action of miltefosine against *C. krusei*.

Materials and Methods {#S2}
=====================

Strains, Media, and Growth Conditions {#S2.SS1}
-------------------------------------

Clinical *C. krusei* isolates were collected from vulvovaginal candidiasis patients as part of routine screening, and ethical approval for their use was not required as per local/national guidelines, and those isolates were stocked in our laboratory. Patient consent was not required as samples were obtained as part of routine screening. All isolates were stored with 15% glycerol at −80°C. *Candida krusei* strains routinely grew on YPD (1% yeast extract, 2% peptone, 2% glucose) media at 30°C. All of the isolates were identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Bruker, Karlsruhe, Germany). RPMI 1640 broth was made for drug susceptibility testing. Miltefosine (Sigma-Aldrich, San Francisco, CA, United States) was dissolved in distilled water and stored at room temperature. The ATCC 6258 strain and ATCC 22019 strains were selected as controls for antifungal susceptibility testing.

Antifungal Susceptibility Testing {#S2.SS2}
---------------------------------

The drug minimum inhibitory concentrations (MICs) of the 57 clinical isolates were determined using the broth microdilution method established by the Clinical & Laboratory Standards Institute (CLSI) M27-A4 document (2017). Minimum inhibitory concentration results for voriconazole were interpreted using clinical breakpoints according to CLSI M60 document ([@B5]), and those for amphotericin B and itraconazole were interpreted using epidemiological cutoff values according to CLSI M59 2nd document ([@B6]). The MIC was defined as the lowest concentration producing 100% growth inhibition for amphotericin B and miltefosine. The endpoint was defined as at least 50% inhibition of growth for voriconazole, itraconazole, and fluconazole. All isolates were incubated at 35°C, and results were read at 24 h for all drugs. For the minimum fungicidal concentrations, after MICs were read, 100 μL of suspension of each well with drug concentrations above the MIC was then plated on YPD plates for 2 days of incubation. Minimum fungicidal concentration was defined as the lowest drug concentration that eliminated 99.9% of the colonies formed on the plates. Quality control was performed for each drug set every time. We repeated all testing three times, and when any two results were consistent, we reported the consistent result.

Antifungal Synergism Testing {#S2.SS3}
----------------------------

Testing for antifungal drug interactions was performed in accordance with the broth microdilution checkerboard method based on aforementioned CLSI M27 document. The final concentration of antifungal drugs ranged from 0.015 to 16 μg/mL for amphotericin B and miltefosine and 1--128 μg/mL for fluconazole. Minimum inhibitory concentration readings were performed at 24 h of incubation. The 100% inhibition endpoint was used for the combination of amphotericin B and miltefosine. And the 50% or more inhibition endpoint was used for miltefosine and fluconazole combinations. To assess the *in vitro* interactions between antifungal drugs, the fractional inhibitory concentration index (FICI) was calculated. The interactions were defined as synergistic if FICI ≤0.5, indifferent if 0.5 \< FICI \< 4.0, and antagonistic if FICI \> 4.0 ([@B21]).

Susceptibility Testing of Preformed Biofilms {#S2.SS4}
--------------------------------------------

Preformed biofilms were grown as described previously with some modifications ([@B24]). Logarithmic growth phase of *C. krusei* cells was harvested and washed three times with phosphate-buffered saline (PBS). Pellets were then resuspended in RPMI-1640 medium with the final density of 1 × 10^6^ cells/mL. A total of 100 μL of the *C. krusei* suspension was pipetted into 96-well clear flat-bottom polystyrene TC-treated microplates (Corning, NY, United States) and incubated at 37°C for 24 h. After incubation, preformed biofilms were washed three times with PBS, and then drugs were added to the wells at different concentrations. The plates were incubated for another 24 h, and the MICs of preformed biofilm were defined as the lowest concentration producing at least 80% reduction in metabolic activity of cells using XTT \[2,3-*bis*-(2-methoxy-4-nitro-5-sulfophenyl)-2*H*-tetrazolium-5-carboxanilide\] reduction assay as described previously ([@B15]).

Sorbitol Assay and Ergosterol Assay {#S2.SS5}
-----------------------------------

To assess the effect of miltefosine on the cell wall or cell membrane of *C. krusei*, the sorbitol assay and ergosterol assay were performed as described previously ([@B34]). The MICs were assessed in the presence of 0.8 M sorbitol or 200 μg/mL ergosterol according to the CLSI document named above. Each well supplemented with sorbitol was incubated at 35°C for 2 and 7 days. And wells supplemented with ergosterol were incubated at 35°C for 24 h. Caspofungi against *C. krusei* ATCC 6258 were used as a positive control in sorbitol assay, and amphotericin B was used as a positive control in ergosterol assay.

Light Microscopy Analysis of Cell Morphology {#S2.SS6}
--------------------------------------------

Cell suspensions at 1 × 10^6^ cells/mL in YPD were treated with 0, 2, and 4 μg/mL miltefosine for 12 h. Then cells were washed and then analyzed using light microscopy.

Cell Chromatin Condensation and Cell Viability Analyses {#S2.SS7}
-------------------------------------------------------

Briefly, the cells \[1 × 10^7^ colony-forming units (CFU)/mL\] were treated with 0, 2, and 4 μg/mL miltefosine in PBS for 5 h. The nuclear condensation was analyzed using propidium iodide (PI) staining. After treatment, cells were washed, suspended in PBS, and incubated with 2 μg/mL PI at the room temperature in the dark for 10 min. Then cells were determined using a fluorescence microscope (Olympus, Tokyo, Japan). To determine cell viability, the cells after treatment were washed, diluted serially, and plated on YPD plates. The plates were incubated for 2 days, and then percentage of survival was evaluated based on CFU counting.

Statistical Analysis {#S2.SS8}
--------------------

Statistical analyses were performed using Student *t* tests by GraphPad Prism 8.0 (GraphPad Software, CA, USA). Differences were considered significant at *P* \< 0.05.

Results {#S3}
=======

Antifungal Susceptibility of Clinical *C. krusei* Isolates {#S3.SS1}
----------------------------------------------------------

The details of comparative susceptibilities to the four common antifungals and miltefosine against 57 *C. krusei* isolates from vulvovaginal candidiasis patients are shown in [Supplementary Table S1](#TS1){ref-type="supplementary-material"}. There was no obvious difference in the susceptibility patterns of *C. krusei* isolates from different years. The antifungal descriptive statistic values for *C. krusei* isolates are shown in [Table 1](#T1){ref-type="table"}. All isolates were inherently resistant to fluconazole (MICs ≥ 16 μg/mL; [Table 1](#T1){ref-type="table"}). All isolates were susceptible and of wild type to voriconazole and itraconazole, respectively. The MIC~90~ values for voriconazole and itraconazole were 0.25 and 0.5 μg/mL, respectively, and the geometric mean was 0.119 and 0.351 μg/mL, respectively. However, amphotericin B did not show good activity against *C. krusei* isolates, with MIC~90~ values of 2 μg/mL and geometric means of 1.905 μg/mL. One isolate (1.8%) was interpreted as non-wild-type phenotype (MIC = 4 μg/mL) to amphotericin B. Miltefosine was found to have activity against clinical *C. krusei* isolates with MIC~90~ value of 2 μg/mL. Its geometric mean value and MIC range were 1.882 and 0.5--2 μg/mL, respectively. Miltefosine showed fungicidal activity against *C. krusei* isolates ([Supplementary Table S1](#TS1){ref-type="supplementary-material"}).

###### 

Antifungal descriptive statistic values for 57 clinical *C. krusei* isolates.

  Drug   Range (μ g/mL)   Median   Mode    MIC~50~   MIC~90~   GM (μ g/mL)
  ------ ---------------- -------- ------- --------- --------- -------------
  ITR    0.125--1         0.5      0.5     0.5       0.5       0.351
  VOR    0.063--0.5       0.125    0.125   0.125     0.25      0.119
  FLC    16--128          32       32      32        64        39.830
  AMB    1--4             2        2       2         2         1.905
  MIL    0.5--2           2        2       2         2         1.882

Median, the value in the middle of the rank; Mode, the value that occurs at the greatest frequency; MIC

50

or MIC

90

, minimal inhibitory concentration of 50% or 90%; GM, geometric mean; ITR, itraconazole; VOR, voriconazole; FLC, fluconazole; AMB, amphotericin B; MIL, miltefosine.

Antifungal Synergy Testing for *C. krusei* Planktonic Cells {#S3.SS2}
-----------------------------------------------------------

We randomly chose 20 isolates for synergy testing of miltefosine and common antifungal drugs against planktonic *C. krusei* isolates by the checkerboard method. Miltefosine and fluconazole combinations showed no synergistic effects against *C. krusei* isolates ([Table 2](#T2){ref-type="table"}). When miltefosine was tested with amphotericin B, synergistic effects were observed in five isolates (25% of the isolates) but not including the amphotericin B non-wild-type isolate ([Table 2](#T2){ref-type="table"}). However, when miltefosine and amphotericin B combination was tested, the MIC of amphotericin B decreased at least eightfold (from 2 to 0.25 μg/mL) in 16 isolates (80% of the isolates).

###### 

The synergy testing results of antifungal drugs against *C. krusei* planktonic cells based on the fractional inhibitory concentration index (FICI) values.

  \(a\)                                                                                                                    
  --------- --------------------- --------- ------------- --------------------- -------- --------- --------- ------------- ---------------
  3         2                     2         0.25/1        0.63                  37       2         2         0.25/1        0.63
  11        2                     2         0.5/0.5       **0.5**               39       2         2         0.25/1        0.63
  17        2                     1         0.25/1        1.13                  41       2         2         0.5/0.5       **0.5**
  21        2                     2         0.25/1        0.63                  42       4         2         0.5/1         0.63
  24        2                     2         0.25/1        0.63                  45       2         2         0.125/0.5     **0.38**
  25        2                     2         0.25/1        0.63                  47       2         2         0.25/1        0.63
  27        2                     2         0.25/1        0.63                  49       2         2         0.5/0.5       **0.5**
  30        1                     2         0.125/0.5     **0.38**              51       2         2         0.25/1        0.63
  32        2                     2         0.25/1        0.63                  54       2         2         0.25/1        0.63
  34        2                     2         0.25/1        0.63                  57       2         2         0.25/1        0.63
                                                                                                                           
  **(b)**                                                                                                                  
            **MIC (μ g/mL) of**                           **MIC (μ g/mL) of**                                              
  **ID**    **FLC**               **MIL**   **FLC/MIL**   **FICI^*a*^**         **ID**   **FLC**   **MIL**   **FLC/MIL**   **FICI^*a*^**
                                                                                                                           
  3         32                    2         \>16/\>1      2                     37       128       2         \>64/\>1      2
  11        16                    2         \>8/\>1       2                     39       64        2         \>32/\>1      2
  17        32                    1         \>16/\>0.5    2                     41       64        2         \>32/\>1      2
  21        32                    2         \>16/\>1      2                     42       128       2         \>64/\>1      2
  24        64                    2         \>32/\>1      2                     45       64        2         \>32/\>1      2
  25        32                    2         \>16/\>1      2                     47       64        2         \>32/\>1      2
  27        32                    2         \>16/\>1      2                     49       32        2         \>16/\>1      2
  30        64                    2         \>32/\>1      2                     51       32        2         \>16/\>1      2
  32        32                    2         \>16/\>1      2                     54       32        2         \>16/\>1      2
  34        32                    2         \>16/\>1      2                     57       64        2         \>32/\>1      2

a

FICI values in bold indicate synergy. AMB, amphotericin B; FLC, fluconazole; MIL, miltefosine.

*In vitro* Interactions of Miltefosine in Combination With Amphotericin B Against *C. krusei* Preformed Biofilms {#S3.SS3}
----------------------------------------------------------------------------------------------------------------

Treatment for preformed biofilms is difficult for hospitalized patients. For this reason, we examined the synergistic activity of miltefosine in combination with amphotericin B on preformed (24-h-old) biofilms of 16 randomly selected *C. krusei* isolates. Synergy of miltefosine in combination with amphotericin B was observed for three isolates (18.8% of the isolates) when grown in biofilm ([Table 3](#T3){ref-type="table"}). Although indifferent effects were observed in the rest of these isolates, the MIC of amphotericin B was reduced eightfold (from 16 to 2 μg/mL) for isolates 25 and 37 and fourfold for other isolates ([Table 3](#T3){ref-type="table"}).

###### 

*In vitro* synergy testing results of miltefosine in combination with amphotericin B against *C. krusei* preformed biofilms.

       MIC (μ g/mL) of              MIC (μ g/mL) of                          
  ---- ----------------- ---- ----- ----------------- ---- ---- ---- ------- -----------
  3    8                 8    2/4   0.75              37   16   8    2/2     **0.375**
  11   8                 8    2/2   **0.5**           39   16   16   8/4     0.75
  17   16                8    8/2   0.75              41   16   8    4/4     0.75
  21   16                16   8/4   0.75              42   8    8    4 / 2   0.75
  24   8                 8    4/2   0.75              45   16   8    4/2     **0.5**
  25   16                8    2/4   0.625             47   16   8    2/4     0.625
  27   8                 8    2/4   0.75              49   8    8    2/4     0.75
  30   8                 8    2/4   0.75              51   16   8    4/4     0.75

a

The 80% inhibition endpoint was used for this combination.

b

FICI values in bold indicate synergy. AMB, amphotericin B; MIL, miltefosine; FICI, fractional inhibitory concentration index.

Exogenous Ergosterol Instead of Sorbitol Reduces the Antifungal Effect of Miltefosine on *C. krusei* Strains {#S3.SS4}
------------------------------------------------------------------------------------------------------------

In order to explore the antifungal mode of action of new drug, exogenous ergosterol and the osmotic protection against the antifungal effect were analyzed as described previously ([@B22]; [@B34]). We next determined whether the addition of exogenous sorbitol (an osmotic protector) or ergosterol to the culture medium would increase the MIC values of miltefosine against *C. krusei* isolates. The presence of sorbitol in the broth microdilution assay did not alter the MIC values of miltefosine against tested clinical isolates in the 2- or 7-day group, as did caspofungin ([Table 4](#T4){ref-type="table"}). However, an eightfold or fourfold MIC increase in miltefosine was observed after the addition of ergosterol in broth microdilution assay among tested isolates ([Table 4](#T4){ref-type="table"}). This behavior is similar to the case of amphotericin B (positive control), which binds directly to ergosterol on the fungal membrane. In this way, miltefosine may bind to ergosterol in the fungal cell membrane instead of in the cell wall biosynthesis pathway.

###### 

Effect of exogenous sorbitol and ergosterol on the MIC (μg/mL) values of miltefosine against clinical *C. krusei* isolates.

  Isolates   Sorbitol   Ergosterol              
  ---------- ---------- ------------ ----- ---- ------
  3          2          2            2     2    16
  17         1          1            1     1    8
  25         2          2            2     2    8
  36         2          2            2     2    16
  43         2          2            2     2    8
  52         2          2            2     2    8
  ATCC6258   2          2            2     2    16
  \*CAS      0.25       \>8          \>8   --   --
  ^\#^AMB    --         --           --    1    \>16

\*CAS, caspofungin, positive control for sorbitol assay;

\#

AMB, amphotericin B, positive control for ergosterol assay.

Miltefosine Treatment Alters the Cell Content and Induces Apoptosis-Like Cell Death in *C. krusei* {#S3.SS5}
--------------------------------------------------------------------------------------------------

The effect of miltefosine on the cell morphology of *C. krusei* strains was assessed using light microscopy. Unlike the untreated cells, the yeast cells treated with miltefosine showed visible changes in cell content ([Figure 1A](#F1){ref-type="fig"}). We also tested the yeast-to-hypha transition of *C. krusei* strains using Spider medium and RPMI 1640 medium, but we did not observe the morphological changes of planktonic cells in hypha-inducing media (data not shown). We also assessed cell apoptosis after miltefosine treatment using PI staining. It was found that cells treated with miltefosine showed red fluorescent spots that indicate chromatin condensation, whereas the untreated cells did not display any fluorescence ([Figure 1B](#F1){ref-type="fig"}). And the cells after treatment exhibited significantly lower cell survival rates compared to the untreated group ([Figure 1C](#F1){ref-type="fig"}), which indicates miltefosine could induce *C. krusei* cell death quickly.

![Miltefosine treatment alters the cell content and induces apoptosis-like cell death in *C. krusei*. **(A)** The *C. krusei* cells of a representative isolate with or without miltefosine treatment were analyzed by light microscopy. Scale bars = 10 μm. **(B)** Cell chromatin condensation was observed by PI staining. Scale bars = 20 μm. **(C)** Percentage of surviving cells was evaluated by CFU counting after treatment with miltefosine. \*\**P* \< 0.01 compared with untreated cells.](fmicb-11-00854-g001){#F1}

Discussion {#S4}
==========

In this study, we assessed the susceptibility of azoles and amphotericin B against *C. krusei* isolates from patients with vulvovaginal candidiasis. We found all isolates were susceptible and of wild type to voriconazole and itraconazole, respectively, which is consistent with other reports on the susceptibility of isolates from invasive candidiasis patients ([@B11]). However, 1.8% of these isolates were of non-wild-type phenotype to amphotericin B. Most of them had a low susceptibility to amphotericin B and had a narrower MIC range than has been reported for isolates from invasive candidiasis patients ([@B11]; [@B13]).

In contrast, miltefosine showed low MICs against all *C. krusei* isolates and had fungicidal activity. The MIC~90~ of our collection of 57 isolates was 2 μg/mL, and its geometric mean was only 1.882 μg/mL. According to the data on clinical safety and pharmacokinetics of miltefosine ([@B4]; [@B20]), the MIC value of miltefosine in this study is much lower than the plasma concentration observed during the treatment of leishmaniasis patients. In addition, miltefosine was shown to have significant antifungal activity against *C. albicans in vitro* and *in vivo* ([@B37]; [@B7]; [@B31]). This indicates that miltefosine should be a good candidate for *in vivo* studies in the future.

We also tested the synergistic activity of miltefosine in combination with azoles and amphotericin B against *C. krusei* isolates. No synergistic effects were found in the group of miltefosine and azoles (data not shown). In contrast, miltefosine has been reported to have synergy with azoles against *Fusarium oxysporum* and the mucormycetes ([@B3]). Here, 25% of the tested isolates were observed to have synergistic activity of miltefosine in combination with amphotericin B against planktonic *C. krusei* isolates. These synergistic effects were consistent with our previous report in *Candida auris* ([@B41]).

Biofilm drug resistance in vulvovaginal candidiasis biofilms is an important virulence factor and a thorny issue for the treatment of vulvovaginal candidiasis ([@B26]). It has been reported that miltefosine is effective against biofilms of four *Candida* species ([@B36]). We found 18.8% of the tested isolates were observed to have synergistic activity of miltefosine in combination with amphotericin B against *C. krusei* preformed biofilms in this study. We also found miltefosine increased the antifungal activity of amphotericin B against most clinical isolates, both planktonic cells and preformed biofilms, by eightfold. Miltefosine in combination with amphotericin B may be a good choice for the treatment of biofilm-related candidiasis, but *in vivo* studies need to be used to evaluate the treatment efficacy in the future.

It has been already established that miltefosine interacts with cell membrane lipids such as sterols in *Leishmania* cells and cancer cells ([@B2]). To determine whether ergosterol of the fungal cell membrane is the target of miltefosine, we performed an ergosterol competition assay. We found that exogenous ergosterol in the culture medium produced MIC values of miltefosine against *C. krusei* cells higher than those produced in ergosterol-free medium, which is consistent with previous studies performed on *Cryptococcus* yeasts ([@B32]). The presence of sorbitol in the medium can provide a protective environment for the cell wall biosynthesis pathway by maintaining the proper osmotic pressure ([@B34]). But no differences in MIC values were observed in either the presence or absence of sorbitol. This suggests miltefosine may not be involved in the cell wall biosynthesis pathway. Those results indicate that the ergosterol of fungal cell membrane may be part of the mode of action of miltefosine against *C. krusei* cells.

In addition, it has been reported that miltefosine has fungicidal activity by inducing apoptosis in *Cryptococcus* species and yeast ([@B42]; [@B32]). Nuclear condensation is one of the hallmarks of apoptosis. We examined nuclear condensation and survival rates of *C. krusei* cells with and without miltefosine treatment, and we observed more nuclear condensation and less cell viability in *C. krusei* cells treated with miltefosine. These results showed that miltefosine could induce apoptosis-like cell death in *C. krusei*. Therefore, apoptosis may be an important mechanism by which miltefosine exerts its antifungal activity against *C. krusei*. However, further studies are required to explore the exact mechanism of action of miltefosine against *Candida* species.

In conclusion, this study demonstrated that miltefosine has a good activity as a fungicidal agent against *C. krusei* isolates. Synergistic effects against both planktonic *C. krusei* cells and biofilms were observed in some isolates when miltefosine was combined with amphotericin B. Mechanism experiments showed that miltefosine may bind to ergosterol in the fungal cell membrane and induce apoptosis-like cell death in *C. krusei*. These findings may provide insight into the possible therapeutic application of miltefosine, but further *in vivo* studies need to be performed.
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